An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
Status:
Terminated
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether trough serum infliximab concentrations at
the time of loss of clinical response will identify pediatric participants with inflammatory
bowel disease (IBD) who would benefit (regain clinical response) from dose escalation above
the currently approved dose [5 milligram (mg)/kilogram (kg) every 8 weeks (q8wk)] and the
safety of that dose escalation.